Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

23.5%

4 terminated/withdrawn out of 17 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

Phase 1
9(52.9%)
Phase 2
5(29.4%)
Phase 3
3(17.6%)
17Total
Phase 1(9)
Phase 2(5)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT03393884Phase 1Active Not Recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Role: lead

NCT06915025Phase 3Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Role: lead

NCT05739981Phase 1Recruiting

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Role: lead

NCT06283459Phase 1Completed

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Role: lead

NCT02480374Phase 1Completed

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Role: lead

NCT02112656Phase 3Completed

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

Role: lead

NCT00617981Phase 3Completed

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Role: lead

NCT04852367Phase 1Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours

Role: collaborator

NCT01464593Phase 2Terminated

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

Role: lead

NCT02850419Phase 2Withdrawn

Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients

Role: lead

NCT02181075Phase 1Completed

Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours

Role: collaborator

NCT00441376Phase 1Completed

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

Role: lead

NCT01640847Phase 2Withdrawn

MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases

Role: lead

NCT00826085Phase 1Completed

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

Role: lead

NCT00036985Phase 2Unknown

Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer

Role: lead

NCT00036998Phase 2Unknown

Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer

Role: lead

NCT00061867Phase 1Completed

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Role: lead

All 17 trials loaded